Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S41-6.

Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies.

Author information

  • University of Cincinnati, Ohio, USA. Jonathan.Bernstein@uc.edu

Abstract

OBJECTIVE:

To provide an overview on the current status of emerging therapies for hereditary angioedema (HAE) in the United States.

DATA SOURCES:

Summary statements were obtained from each pharmaceutical company regarding their agent.

STUDY SELECTION:

Each agent is undergoing or has completed phase 3, double-blind, placebo-controlled trials.

RESULTS:

Berinert P, a purified, virus-inactivated, human plasma-derived C1 inhibitor (C1-INH) concentrate, is being investigated in 2 international, multicenter, prospective trials. Experience with this agent in Europe and Canada indicates it is effective and safe. Cinryze is a nanofiltered C1-INH replacement therapy demonstrated to be effective and safe in acute and prophylactic arms of a phase 3, double-blind, placebo-controlled study. Rhucin, a recombinant human C1-INH replacement therapy from transgenic rabbits, has been shown to be effective and safe in phase 2 and phase 2/3 studies, with an additional phase 3 study ongoing. DX-88 or ecallantide, a potent and specific inhibitor of plasma kallikrein, achieved all primary and secondary efficacy end points in a placebo-controlled, double-blind, phase 3 study, with a second phase 3 study ongoing. Icatibant, a potent and specific peptidomimetic bradykinin 2 receptor antagonist, was studied in 2 phase 3 trials: FAST 1 (For Angioedema Subcutaneous Treatment) did not achieve statistical significance for the primary end point but did so for secondary end points, whereas FAST 2 achieved statistical significance for primary and secondary end points.

CONCLUSIONS:

The future treatment of HAE in the United States appears promising based on progress being made in drug development for this orphan disease.

PMID:
18220151
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk